I am loving what I am reading
Novo Nordisk CEO Mike Doustdar thinks that in the coming years obesity will look like mental health once did, where people labeled it as one condition
It can increase the enzyme activity of glutathione peroxidase and reduce ROS production [17, 18]
Without RCT data on semaglutide for the management of BAD, it is difficult to evaluate its safety and efficacy compared with other BAD therapeutics, but the abovementioned case underscores that newer, longer-acting, and more potent GLP-1RAs not necessarily provide better treatment results in BAD as compared with older, shorter-acting, and less potent GLP-1RAs such as liraglutide
[DOI] [PMC free article] [PubMed] [Google Scholar] 49.Izquierdo J.L., Soriano J.B., Gonzlez Y., Lumbreras S., Ancochea J., Echeverry C., et al
But those mechanisms require substrate (stored fat being mobilized through caloric deficit) to act upon